2-amino-N-[(2R)-1-[[1-[1-(4-methoxyphenyl)-2-(4-methylpiperidin-1-yl)-2-oxoethyl]imidazol-4-yl]amino]-1-oxo-3-phenylmethoxypropan-2-yl]-2-methylpropanamide | 1431845-73-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-N-[(2R)-1-[[1-[1-(4-methoxyphenyl)-2-(4-methylpiperidin-1-yl)-2-oxoethyl]imidazol-4-yl]amino]-1-oxo-3-phenylmethoxypropan-2-yl]-2-methylpropanamide
• CAS: 1431845-73-6
• 化学式: C₃₂H₄₂N₆O₅
• 分子量: 590.723
• InChiKey: DSYJTBAYGWNDFQ-HSLSYKTRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  141
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-amino-N-[(2R)-1-[[1-[1-(4-methoxyphenyl)-2-(4-methylpiperidin-1-yl)-2-oxoethyl]imidazol-4-yl]amino]-1-oxo-3-phenylmethoxypropan-2-yl]-2-methylpropanamide 生成 2-Amino-N-[2-benzyloxy-(1R)-[1-[(1R)-(4-methoxyphenyl)-2-(4-methylpiperidin-1-yl)-2-oxo-ethyl]-1H-imidazol-4-ylcarbamoyl]ethyl]-2-methylpropionamide 、
  参考文献：
  名称：

  Growth hormone secretagogues

  摘要：

  揭示的是生长激素促分泌素及其用途的公式，其中R1为C6H5CH2OCH2—，C6H5(CH2)3—或吲哚-3-基甲基；Y为吡咯烷-1-基，4-C1-C6烷基哌啶-1-基或NR2R2；R2各自独立为C1到C6烷基；R3为2-萘基或对位由W取代的苯基；W为H，F，CF3，C1-C6烷氧基或苯基；R4为H或CH3，或其药用可接受的盐或溶剂。

  公开号：

  US06828331B1
• 作为产物：
  描述：

  tert-butyl N-[1-[[(2R)-1-[[1-[1-(4-methoxyphenyl)-2-(4-methylpiperidin-1-yl)-2-oxoethyl]imidazol-4-yl]amino]-1-oxo-3-phenylmethoxypropan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以99%的产率得到2-amino-N-[(2R)-1-[[1-[1-(4-methoxyphenyl)-2-(4-methylpiperidin-1-yl)-2-oxoethyl]imidazol-4-yl]amino]-1-oxo-3-phenylmethoxypropan-2-yl]-2-methylpropanamide
  参考文献：
  名称：

  Growth hormone secretagogues

  摘要：

  揭示的是生长激素促分泌素及其用途的公式，其中R1为C6H5CH2OCH2—，C6H5(CH2)3—或吲哚-3-基甲基；Y为吡咯烷-1-基，4-C1-C6烷基哌啶-1-基或NR2R2；R2各自独立为C1到C6烷基；R3为2-萘基或对位由W取代的苯基；W为H，F，CF3，C1-C6烷氧基或苯基；R4为H或CH3，或其药用可接受的盐或溶剂。

  公开号：

  US06828331B1

文献信息

• GROWTH HORMONE SECRETAGOGUES
  申请人：ELI LILLY AND COMPANY

  公开号：EP1153034B1

  公开（公告）日：2007-10-17
• METHODS OF TREATING NEURODEGENERATIVE CONDITIONS
  申请人：Oxeia Biopharmaceuticals, Inc.

  公开号：US20170121385A1

  公开（公告）日：2017-05-04

  The present disclosure provides methods for treating a neurodegenerative condition or situation in a subject in need thereof, comprising administering to the subject an effective amount of a compound comprising ghrelin or a ghrelin variant.
• METHODS OF TREATING TRAUMATIC BRAIN INJURY
  申请人：OXEIA BIOPHARMACEUTICALS, INC.

  公开号：US20170266257A1

  公开（公告）日：2017-09-21

  The present disclosure provides methods for treating traumatic brain injury and other neurological disorders in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising ghrelin or a ghrelin variant. This invention provides for methods for treating a severe or moderate traumatic brain injury in a patient wherein said method comprises administering to the subject suffering from said severe or moderate traumatic brain injury a therapeutic effective amount of ghrelin or a ghrelin variant or a composition comprising ghrelin or a ghrelin variant so as to treat said severe or moderate traumatic brain injury.
• METHODS OF TREATING MILD BRAIN INJURY
  申请人：OXEIA BIOPHARMACEUTICALS, INC.

  公开号：US20170281732A1

  公开（公告）日：2017-10-05

  The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject in need thereof, comprising administering to the subject an effective amount of a compound comprising a ghrelin or ghrelin variant. This invention provides for methods for treating a mild brain injury or concussion in a patient wherein said method comprises administering to the subject in need thereof suffering from said mild brain injury or concussion an effective amount of a ghrelin variant or a composition comprising a ghrelin variant so as to treat said mild brain injury or concussion.